2-(n-myristoylamino)-1-phenyl-1-propanol profile

2-(N-myristoylamino)-1-phenyl-1-propanol: ceramidase inhibitor; RN given for ((R*,S*)-(+-))-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	124735
CHEMBL ID	429926
CHEBI ID	93338
SCHEMBL ID	611869
MeSH ID	M0261565

Synonym
CBIOL_001751
BRD-K76274772-001-02-7
BIO1_000037
BIO1_000526
BIO1_001015
BIO2_000128
BIO2_000608
BSPBIO_001408
NCGC00161371-01
NCGC00161371-02
d-erythro-mapp
KBIO2_005264
KBIO3_000255
KBIO2_002696
KBIOGR_000128
KBIOSS_000128
KBIO2_000128
KBIO3_000256
IDI1_033878
NCGC00161371-03
HMS1989G10
60847-25-8
BML3-E01
mapp, d-erythro
HMS1361G10
HMS1791G10
CHEMBL429926 ,
n-[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]tetradecanamide
143492-38-0
(1s,2r-d-erythro-2-n-myristoylamino)-1-phenyl-1-propanol
bdbm50392473
2-(n-myristoylamino)-1-phenyl-1-propanol
(r,s)-(+-)-n-(2-hydroxy-1-methyl-2-phenylethyl)tetradecanamide
tetradecanamide, n-(2-hydroxy-1-methyl-2-phenylethyl)-, (r,s)-(+-)-
SCHEMBL611869
d-erythro-2-tetradecanoylamino-1-phenyl-1-propanol
143492-39-1
HMS3648G09
HMS3402G10
gtpl8817
d-e-mapp
CHEBI:93338
J-007821
n-(1-hydroxy-1-phenylpropan-2-yl)tetradecanimidic acid
DTXSID00931906
Q27077017
sr-01000946211
SR-01000946211-1
MS-25732
n-((1s,2r)-1-hydroxy-1-phenylpropan-2-yl)tetradecanamide
CS-0138591
HY-137422
AKOS040755605

Class	Description
alkylbenzene	A monocyclic arene that is benzene substituted with one or more alkyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	44.6684	0.0112	12.4002	100.0000	AID1030
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Acid ceramidase	Homo sapiens (human)	IC50 (µMol)	333.6667	0.0207	0.4925	1.0000	AID1707269; AID1707270; AID691433
Alkaline ceramidase 2	Homo sapiens (human)	IC50 (µMol)	1.0000	1.0000	1.0000	1.0000	AID734964
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
fatty acid metabolic process	Acid ceramidase	Homo sapiens (human)
keratinocyte differentiation	Acid ceramidase	Homo sapiens (human)
sphingosine biosynthetic process	Acid ceramidase	Homo sapiens (human)
ceramide biosynthetic process	Acid ceramidase	Homo sapiens (human)
ceramide catabolic process	Acid ceramidase	Homo sapiens (human)
regulation of steroid biosynthetic process	Acid ceramidase	Homo sapiens (human)
regulation of programmed necrotic cell death	Acid ceramidase	Homo sapiens (human)
cellular response to tumor necrosis factor	Acid ceramidase	Homo sapiens (human)
negative regulation of cell-matrix adhesion	Alkaline ceramidase 2	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Alkaline ceramidase 2	Homo sapiens (human)
DNA damage response	Alkaline ceramidase 2	Homo sapiens (human)
positive regulation of cell population proliferation	Alkaline ceramidase 2	Homo sapiens (human)
regulation of autophagy	Alkaline ceramidase 2	Homo sapiens (human)
sphingolipid catabolic process	Alkaline ceramidase 2	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Alkaline ceramidase 2	Homo sapiens (human)
response to retinoic acid	Alkaline ceramidase 2	Homo sapiens (human)
negative regulation of cell adhesion mediated by integrin	Alkaline ceramidase 2	Homo sapiens (human)
regulation of apoptotic process	Alkaline ceramidase 2	Homo sapiens (human)
sphingosine biosynthetic process	Alkaline ceramidase 2	Homo sapiens (human)
ceramide catabolic process	Alkaline ceramidase 2	Homo sapiens (human)
regulation of protein glycosylation	Alkaline ceramidase 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Alkaline ceramidase 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Acid ceramidase	Homo sapiens (human)
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides	Acid ceramidase	Homo sapiens (human)
N-acylsphingosine amidohydrolase activity	Acid ceramidase	Homo sapiens (human)
fatty acid amide hydrolase activity	Acid ceramidase	Homo sapiens (human)
ceramidase activity	Acid ceramidase	Homo sapiens (human)
N-acylsphingosine amidohydrolase activity	Alkaline ceramidase 2	Homo sapiens (human)
metal ion binding	Alkaline ceramidase 2	Homo sapiens (human)
dihydroceramidase activity	Alkaline ceramidase 2	Homo sapiens (human)
ceramidase activity	Alkaline ceramidase 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
early endosome	Acid ceramidase	Homo sapiens (human)
endoplasmic reticulum	Acid ceramidase	Homo sapiens (human)
extracellular region	Acid ceramidase	Homo sapiens (human)
extracellular space	Acid ceramidase	Homo sapiens (human)
nucleus	Acid ceramidase	Homo sapiens (human)
lysosome	Acid ceramidase	Homo sapiens (human)
lysosomal lumen	Acid ceramidase	Homo sapiens (human)
extracellular exosome	Acid ceramidase	Homo sapiens (human)
tertiary granule lumen	Acid ceramidase	Homo sapiens (human)
ficolin-1-rich granule lumen	Acid ceramidase	Homo sapiens (human)
Golgi membrane	Alkaline ceramidase 2	Homo sapiens (human)
Golgi apparatus	Alkaline ceramidase 2	Homo sapiens (human)
Golgi membrane	Alkaline ceramidase 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay ID	Title	Year	Journal	Article
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1707269	Inhibition of acid ceramidase in human HL-60 cell lysates	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors.
AID320186	Decrease in endogenous sphingosine level in human MCF7 cells upto 50 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID1707270	Inhibition of acid ceramidase in human HaCaT cell lysates	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors.
AID320173	Increase in endogenous ceramide level in human MCF7 cells at >25 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID691433	Inhibition of aCDase expressed in human HL60 cell extract	2012	Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20	Novel amide- and sulfonamide-based aromatic ethanolamines: effects of various substituents on the inhibition of acid and neutral ceramidases.
AID320185	Increase in endogenous C24:1-ceramide level in human MCF7 cells upto 5 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID691427	Inhibition of recombinant human aCDase expressed in Sf9 cells using fluorescently-labeled acyl-NBD-C12-ceramide as substrate at 80 uM after 8 hrs by fluorescence assay	2012	Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20	Novel amide- and sulfonamide-based aromatic ethanolamines: effects of various substituents on the inhibition of acid and neutral ceramidases.
AID320259	Increase in endogenous C24-ceramide level in human MCF7 cells at 50 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID320174	Decrease in endogenous sphingosine level in human MCF7 cells at >2.5 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID320188	Decrease in endogenous C24-ceramide level in human MCF7 cells at 10 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID734977	Inhibition of human recombinant neutral ceramidase using Acyl-NBD-C12-cer as substrate at 80 uM after 2 hrs by fluorescence assay	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Effective inhibition of acid and neutral ceramidases by novel B-13 and LCL-464 analogues.
AID734964	Inhibition of alkaline ceramidase 2 in human HL-60 cells using 3H]C16-ceramide as substrate after 1 hr by liquid scintillation counting analysis	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Effective inhibition of acid and neutral ceramidases by novel B-13 and LCL-464 analogues.
AID320183	Decrease in endogenous C24-ceramide level in human MCF7 cells upto 5 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID320184	Decrease in endogenous sphingosine level in human MCF7 cells upto 5 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID734976	Inhibition of human recombinant acid ceramidase using Acyl-NBD-C12-cer as substrate at 80 uM after 8 hrs by fluorescence assay	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Effective inhibition of acid and neutral ceramidases by novel B-13 and LCL-464 analogues.
AID320182	Decrease in endogenous C16-ceramide level in human MCF7 cells upto 5 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID320113	Antiproliferative activity against human MCF7 cells after 48 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents.
AID320189	Decrease in endogenous C24:1-ceramide level in human MCF7 cells at 10 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID320187	Decrease in endogenous C16-ceramide level in human MCF7 cells at 10 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (9.09)	18.2507
2000's	11 (50.00)	29.6817
2010's	6 (27.27)	24.3611
2020's	3 (13.64)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	23 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Description	Relationhip Strength	Studies	Classes	Roles
carmofur	[no description available]	medium	1	organohalogen compound; pyrimidines
n-oleoylethanolamine	[no description available]	medium	2	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-acylethanolamine 18:1	EC 3.5.1.23 (ceramidase) inhibitor; geroprotector; PPARalpha agonist
glycolipids	[no description available]	medium	2
imipramine	[no description available]	medium	1	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
1-phenyl-2-decanoylamino-3-morpholino-1-propanol	[no description available]	medium	1
sphingosine	[no description available]	medium	5	sphing-4-enine	human metabolite; mouse metabolite
sphingosine 1-phosphate	[no description available]	medium	1	sphingoid 1-phosphate	mouse metabolite; signalling molecule; sphingosine-1-phosphate receptor agonist; T-cell proliferation inhibitor; vasodilator agent
n-acetylsphingosine	[no description available]	medium	4	N-acylsphingosine
n-acetylneuraminic acid	[no description available]	medium	1	N-acetylneuraminic acids	antioxidant; bacterial metabolite; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; human metabolite; mouse metabolite
fumonisin b1	[no description available]	medium	1	diester; fumonisin; primary amino compound; triol	carcinogenic agent; metabolite
n-caproylsphingosine	[no description available]	medium	2	N-acylsphingosine
n,n-dimethylsphingenine	[no description available]	medium	1	aminodiol; sphingoid; tertiary amino compound	EC 2.7.1.91 (sphingosine kinase) inhibitor; metabolite
1-deoxynojirimycin	[no description available]	medium	1	2-(hydroxymethyl)piperidine-3,4,5-triol; piperidine alkaloid	anti-HIV agent; anti-obesity agent; bacterial metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; plant metabolite
miglustat	[no description available]	medium	1	piperidines; tertiary amino compound	anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
cycloserine	[no description available]	medium	1	4-amino-1,2-oxazolidin-3-one; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic; zwitterion	antiinfective agent; antimetabolite; antitubercular agent; metabolite; NMDA receptor agonist
thermozymocidin	[no description available]	medium	1	alpha-amino fatty acid; hydroxy monocarboxylic acid; non-proteinogenic alpha-amino acid; sphingoid	antifungal agent; antimicrobial agent; antineoplastic agent; apoptosis inducer; EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor; fungal metabolite; immunosuppressive agent
n-hexanoyldihydrosphingosine	[no description available]	medium	1	N-acylsphinganine
1-phenyl-2-palmitoylamino-3-morpholino-1-propanol	[no description available]	medium	2	benzyl alcohols; fatty amide; morpholines; secondary alcohol; tertiary amino compound
sphingosine kinase	[no description available]	medium	1
sr 33557	[no description available]	medium	1
fumonisin b2	[no description available]	medium	1	diester; diol; fumonisin; primary amino compound	Aspergillus metabolite; carcinogenic agent
n-palmitoylsphingosine	[no description available]	medium	1	Cer(d34:1); N-acylsphingosine; N-palmitoyl-sphingoid base	human blood serum metabolite; Mycoplasma genitalium metabolite
fludarabine	[no description available]	medium	1	purine nucleoside
vidarabine	[no description available]	medium	1	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
guanosine triphosphate	[no description available]	medium	1	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
transferrin	[no description available]	medium	1
lactic acid	[no description available]	medium	1	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
tyrphostin ag 1024	[no description available]	low	0	alkylbenzene
benzethonium	[no description available]	low	0	alkylbenzene
isoxsuprine	[no description available]	low	0	alkylbenzene
nylidrin	[no description available]	low	0	alkylbenzene
oxeladin	[no description available]	low	0	alkylbenzene
2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol	[no description available]	low	0	alkylbenzene
octoxynol	[no description available]	low	0	alkylbenzene
tyrphostin a9	[no description available]	low	0	alkylbenzene	geroprotector
valethamate	[no description available]	low	0	alkylbenzene
xylometazoline	[no description available]	low	0	alkylbenzene
hydroxyphenamate	[no description available]	low	0	alkylbenzene
isoaminile	[no description available]	low	0	alkylbenzene
phenaglycodol	[no description available]	low	0	alkylbenzene
p-tert-amylphenol	[no description available]	low	0	alkylbenzene
2-tert-butylphenol	[no description available]	low	0	alkylbenzene
2,6-di-tert-butyl-4-hydroxymethylphenol	[no description available]	low	0	alkylbenzene
2,4-di-tert-butylphenol	[no description available]	low	0	alkylbenzene; phenols	antioxidant; bacterial metabolite; marine metabolite
4-tert-butylbenzoic acid	[no description available]	low	0	alkylbenzene
cumene	[no description available]	low	0	alkylbenzene
ethylbenzene	[no description available]	low	0	alkylbenzene
n-propylbenzene	[no description available]	low	0	alkylbenzene
n-butylbenzene	[no description available]	low	0	alkylbenzene
proxazole	[no description available]	low	0	alkylbenzene
sec-butylbenzene	[no description available]	low	0	alkylbenzene
sulfurous acid, 2-(p-tert-butylphenoxy)-1-methylethyl 2-chloroethyl ester	[no description available]	low	0	alkylbenzene
4-tert-octylphenol	[no description available]	low	0	alkylbenzene
crufomate	[no description available]	low	0	alkylbenzene
isoxsuprine hydrochloride	[no description available]	low	0	alkylbenzene
4-propylphenol	[no description available]	low	0	alkylbenzene
promecarb	[no description available]	low	0	alkylbenzene
o-cymen-5-ol	[no description available]	low	0	alkylbenzene
butethamate citrate	[no description available]	low	0	alkylbenzene
butamirate	[no description available]	low	0	alkylbenzene
2,6-di-tert-butylphenol	[no description available]	low	0	alkylbenzene; phenols	antioxidant
lifibrol	[no description available]	low	0	alkylbenzene
ephedrine hydrochloride	[no description available]	low	0	alkylbenzene
simetride	[no description available]	low	0	alkylbenzene
fenoxazoline	[no description available]	low	0	alkylbenzene
tris-(2,4-di-tert-butylphenyl) phosphite	[no description available]	low	0	alkylbenzene
fenpropimorph	[no description available]	low	0	alkylbenzene
3-(2-hydroxy-4-(1,1-dimethylheptylphenyl)cyclohexan-1-ol)	[no description available]	low	0	alkylbenzene; ring assembly
4-propylbenzoic acid	[no description available]	low	0	alkylbenzene
2-n-hexyl-5-n-propylresorcinol	[no description available]	low	0	alkylbenzene
4-[[bis(2-hydroxyethyl)amino]methyl]-2,6-ditert-butylphenol	[no description available]	low	0	alkylbenzene
(1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol	[no description available]	low	0	alkylbenzene
oxilofrine	[no description available]	low	0	alkylbenzene
2-[(dimethylamino)methyl]-4-methyl-6-(1-methylcyclohexyl)phenol	[no description available]	low	0	alkylbenzene; ring assembly
1-(1-azepanyl)-2-(2-bromo-4-propan-2-ylphenoxy)ethanone	[no description available]	low	0	alkylbenzene
N-[5-(4-tert-butylphenyl)-1,3,4-thiadiazol-2-yl]-2-methoxyacetamide	[no description available]	low	0	alkylbenzene
4-(4-tert-butylphenoxy)-N-(4,5-dihydrothiazol-2-yl)butanamide	[no description available]	low	0	alkylbenzene
2-(2-bromo-4-tert-butylphenoxy)-N-(2-furanylmethyl)acetamide	[no description available]	low	0	alkylbenzene
N-[[[2-(2-bromo-4-propan-2-ylphenoxy)-1-oxoethyl]hydrazo]-sulfanylidenemethyl]-2-furancarboxamide	[no description available]	low	0	alkylbenzene
N-[3-[[diethylamino(sulfanylidene)methyl]thio]-1-oxopropyl]carbamic acid (4-propan-2-ylphenyl) ester	[no description available]	low	0	alkylbenzene
N-[3-[[diethylamino(sulfanylidene)methyl]thio]-1-oxopropyl]carbamic acid (4-tert-butylphenyl) ester	[no description available]	low	0	alkylbenzene
3-(4-tert-butylphenoxy)-N-(4,5-dihydrothiazol-2-yl)propanamide	[no description available]	low	0	alkylbenzene
2-[[2-[[5-(4-tert-butylphenyl)-2-methoxycarbonyl-3-thiophenyl]amino]-2-oxoethyl]thio]acetic acid	[no description available]	low	0	alkylbenzene
1-(4-tert-butylphenoxy)-3-(1H-1,2,4-triazol-5-ylthio)-2-propanol	[no description available]	low	0	alkylbenzene
N-(2-methoxycyclohexyl)-2,5-dimethylaniline	[no description available]	low	0	alkylbenzene
tinofedrine	[no description available]	low	0	alkylbenzene
fospropofol	[no description available]	low	0	alkylbenzene
cgp 13501	[no description available]	low	0	alkylbenzene
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol	[no description available]	low	0	alkylbenzene; ring assembly
cgp 7930	[no description available]	low	0	alkylbenzene
nylidrin hydrochloride	[no description available]	low	0	alkylbenzene
methylbenzethonium chloride	[no description available]	low	0	alkylbenzene
tapentadol	[no description available]	low	0	alkylbenzene
o-demethyltramadol	[no description available]	low	0	alkylbenzene; ring assembly
elsibucol	[no description available]	low	0	alkylbenzene
2-(4-butan-2-ylanilino)-3-pyridinecarbonitrile	[no description available]	low	0	alkylbenzene
oxaziclomefone	[no description available]	low	0	alkylbenzene

Condition	Relationship Strength	Studies
B-Cell Chronic Lymphocytic Leukemia	low	1
B-Cell Leukemia, Chronic	low	1
B-Cell Malignancy, Low-Grade	low	1
B-Lymphocytic Leukemia, Chronic	low	1
Cancer of Colon	low	1
Cancer of Head	low	1
Cancer of Head and Neck	low	1
Cancer of Lung	low	1
Cancer of Neck	low	1
Cancer of the Colon	low	1
Cancer of the Head	low	1
Cancer of the Head and Neck	low	1
Cancer of the Lung	low	1
Cancer of the Neck	low	1
Carcinoma, Epidermoid	low	1
Carcinoma, Non-Small Cell Lung	low	1
Carcinoma, Non-Small-Cell Lung	low	1
Carcinoma, Planocellular	low	1
Carcinoma, Squamous	low	1
Carcinoma, Squamous Cell	low	1
Chronic Lymphocytic Leukemia	low	1
Colon Cancer	low	1
Colon Neoplasms	low	1
Colonic Cancer	low	1
Colonic Neoplasms	low	1
Congenital Zika Syndrome	low	1
Congenital Zika Virus Infection	low	1
Diffuse Well-Differentiated Lymphocytic Lymphoma	low	1
Disease Models, Animal	low	1
Disrupted In B-Cell Malignancy	low	1
Encephalitis, Polio	low	1
Epidemic Acute Poliomyelitis	low	1
Experimental Hepatoma	low	1
Experimental Hepatomas	low	1
Experimental Liver Neoplasms	low	1
Fever, Zika	low	1
Head and Neck Cancer	low	1
Head and Neck Neoplasm	low	1
Head and Neck Neoplasms	low	1
Head Cancer	low	1
Head Neoplasm	low	1
Head Neoplasms	low	1
Head, Neck Neoplasms	low	1
Hepatoma, Experimental	low	1
Hepatoma, Morris	low	1
Hepatoma, Novikoff	low	1
Hepatomas, Experimental	low	1
Infantile Paralysis	low	1
Leukemia, B Cell, Chronic	low	1
Leukemia, B-Cell, Chronic	low	1
Leukemia, Chronic Lymphatic	low	1
Leukemia, Chronic Lymphocytic	low	1
Leukemia, Chronic Lymphocytic, B-Cell	low	1
Leukemia, Lymphoblastic, Chronic	low	1
Leukemia, Lymphocytic, Chronic	low	1
Leukemia, Lymphocytic, Chronic, B Cell	low	1
Leukemia, Lymphocytic, Chronic, B-Cell	low	1
Liver Neoplasms, Experimental	low	1
Lung Cancer	low	1
Lung Neoplasms	low	1
Lymphoblastic Leukemia, Chronic	low	1
Lymphocytic Leukemia, Chronic	low	1
Lymphocytic Leukemia, Chronic, B Cell	low	1
Lymphocytic Leukemia, Chronic, B-Cell	low	1
Lymphocytic Lymphoma	low	1
Lymphocytic Lymphoma, Diffuse, Well Differentiated	low	1
Lymphocytic Lymphoma, Diffuse, Well-Differentiated	low	1
Lymphocytic Lymphoma, Well Differentiated	low	1
Lymphocytic Lymphoma, Well-Differentiated	low	1
Lymphoma, Lymphocytic	low	1
Lymphoma, Lymphocytic, Diffuse, Well Differentiated	low	1
Lymphoma, Lymphocytic, Diffuse, Well-Differentiated	low	1
Lymphoma, Lymphocytic, Well Differentiated	low	1
Lymphoma, Lymphocytic, Well-Differentiated	low	1
Lymphoma, Lymphoplasmacytoid, CLL	low	1
Lymphoma, Small Lymphocytic	low	1
Lymphoma, Small Lymphocytic, Plasmacytoid	low	1
Lymphoma, Small-Cell	low	1
Lymphoplasmacytoid Lymphoma, CLL	low	1
Malignant Melanoma	low	1
Melanoma	low	1
Neck Cancer	low	1
Neck Neoplasm	low	1
Neck Neoplasms	low	1
Neoplasms, Colonic	low	1
Neoplasms, Experimental Liver	low	1
Neoplasms, Head	low	1
Neoplasms, Head and Neck	low	1
Neoplasms, Lung	low	1
Neoplasms, Neck	low	1
Neoplasms, Pulmonary	low	1
Neoplasms, Upper Aerodigestive Tract	low	1
Non-Small Cell Lung Cancer	low	1
Non-Small Cell Lung Carcinoma	low	1
Non-Small-Cell Lung Carcinoma	low	1
Nonsmall Cell Lung Cancer	low	1
Polio	low	1
Polio Encephalitis	low	1
Poliomyelitis	low	1
Poliomyelitis Infection	low	1
Poliomyelitis, Acute	low	1
Poliomyelitis, Nonpoliovirus	low	1
Poliomyelitis, Preparalytic	low	1
Pulmonary Cancer	low	1
Pulmonary Neoplasms	low	1
Small-Cell Lymphoma	low	1
Squamous Cell Carcinoma	low	1
UADT Neoplasm	low	1
UADT Neoplasms	low	1
Upper Aerodigestive Tract Neoplasm	low	1
Upper Aerodigestive Tract Neoplasms	low	1
Zika Fever	low	1
Zika Virus Disease	low	1
Zika Virus Infection	low	1
ZikV Infection	low	1

2-(n-myristoylamino)-1-phenyl-1-propanol

Description

Cross-References

Synonyms (53)

Drug Classes (1)

Protein Targets (3)

Potency Measurements

Inhibition Measurements

Biological Processes (20)

Molecular Functions (7)

Ceullar Components (12)

Bioassays (23)

Research

Studies (22)

Study Types

Research Highlights

Dosage (1)

Article	Year
Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue: 2	2008
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

2-(n-myristoylamino)-1-phenyl-1-propanol

Description

Cross-References

Synonyms (53)

Drug Classes (1)

Protein Targets (3)

Potency Measurements

Inhibition Measurements

Biological Processes (20)

Molecular Functions (7)

Ceullar Components (12)

Bioassays (23)

Research

Studies (22)

Study Types

Related Drugs (97)

Related Conditions (115)

Research Highlights

Dosage (1)